Zydus Lifesciences Limited

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:54 2024-05-17 am EDT			5-day change	1st Jan Change
1,051 ^INR	+4.20%		+8.59%	+52.55%

May. 13	Zydus Lifesciences Gets US FDA Nod to Market Dexamethasone Tablets	MT
May. 10	India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says	RE

Cadila Healthcare Ltd Announces Resignation of Apurva S. Diwanji as Director

December 04, 2014 at 05:53 am EST

Cadila Healthcare Ltd. announced that the Directors of the Company approved the resignation of Shri. Apurva S. Diwanji as Director. The resignation has been received and taken on record on December 04, 2014.

Latest news about Zydus Lifesciences Limited

Zydus Lifesciences Gets US FDA Nod to Market Dexamethasone Tablets	May. 12	MT
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says	May. 10	RE
Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis	May. 09	CI
Zydus Lifesciences Gets US FDA Final Nod for Acne Treatment Gel	May. 09	MT
Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5%	May. 09	CI
Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug	May. 06	MT
Zydus Lifesciences Limited Receives A Demand Order-In-Original for the Financial Year 2018-19	Apr. 29	CI
Zydus Lifesciences Limited Receives A Demand Order-In-Original for the Financial Year 2018-19	Apr. 29	CI
Weak March Quarter Earnings Weigh Down Indian Equities on Friday	Apr. 26	MT
Zydus Lifesciences Gets US FDA's Final Approval for Generic Acne Cream	Apr. 26	MT
Zydus Lifesciences Limited Receives Final Approval from USFDA for Tretinoin Cream USP, 0.1%	Apr. 26	CI
Zydus Lifesciences Limited Receives Demand Order-In-Original for the Financial Year 2018-19	Apr. 25	CI
Zydus Lifesciences Gets 10 Observations from US FDA After Jarod, India Manufacturing Site Inspection	Apr. 24	MT
China Medical System's Anti-Anaemia NDA Accepted in China	Apr. 23	MT
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	Apr. 23	MT
Zydus Lifesciences Limited Announces New Drug Application of Zydus' Innovative Drug Desidustat Tablets by China Medical System Holdings Limited Accepted in China	Apr. 23	CI
Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S	Apr. 22	CI
Zydus Arm Get UK Drug Regulator's Marketing Approval for Nulibry as MoCD Type A Treatment	Apr. 21	MT
Zydus Lifesciences Launches Generic Drug for Overactive Bladder in US	Apr. 21	MT
Zydus Receives Approval from WHO International Non-Proprietary Names for Usnoflast as Recommended Name for ZYIL1	Apr. 01	CI
Zydus Gets Four Observations from US FDA for Oncology Injectable Plant	Mar. 28	MT
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Letermovir Tablets, 240 Mg and 480 Mg	Mar. 23	CI
Zydus Lifesciences Gets US FDA's Final Nod for Finasteride and Tadalafil Capsules	Mar. 17	MT
Zydus Lifesciences Limited Receives Final Approval from USFDA and 180 Days CGT Exclusivity for Finasteride and Tadalafil Cap Capsules	Mar. 16	CI
Tranche Update on Zydus Lifesciences Limited's Equity Buyback Plan announced on February 9, 2024.	Mar. 15	CI

Chart Zydus Lifesciences Limited

Duration

Period

More charts

Company Profile

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Sector

Pharmaceuticals

Calendar

2024-05-16 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Zydus Lifesciences Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,009 INR

Average target price

850.3 INR

Spread / Average Target

-15.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZYDUS LIFESCIENCES LIMITED	+52.55%	12.16B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.59%	44.15B
OTSUKA HOLDINGS CO., LTD.	+23.03%	23.02B
SANDOZ GROUP AG	+18.22%	15.33B
CIPLA LIMITED	+12.26%	13.74B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.88%	5.66B
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT.	+7.89%	4.85B

Generic Pharmaceuticals

Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Cadila Healthcare Ltd Announces Resignation of Apurva S. Diwanji as Director

EPS Revisions